My Treatment Approach: My Treatment Approach: Navigating Genetic Testing and RET-Targeted Treatments in NSCLC - Episode 4

Practical Considerations in Metastatic NSCLC: Access and Timing of Testing

December 17, 2024

Heather A. Wakelee, MD, FASCO, Jacob Sands, MD

Panelists discuss strategies for clinicians without access to in-house molecular testing, focusing on how to ensure appropriate turnaround times when outsourcing tests and share insights on the typical timeline for receiving biomarker testing results at their respective institutions.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Patient Case: 67 Year-Old Male With Stage IIIB+ NSCLC Awaiting for Mutation Testing

EP. 2: Next Steps to Stage IIIB NSCLC Patient Case Awaiting Molecular Testing and Usability of Liquid Biopsy

EP. 3: Testing Methodologies and Standards in Metastatic NSCLC

Now Viewing

EP. 4: Practical Considerations in Metastatic NSCLC: Access and Timing of Testing

EP. 5: Clinical-Decision Making: When to Treat Advanced NSCLC Without Mutational Results

EP. 6: Initial Approach to Management of RET-Positive NSCLC

EP. 7: Patient and Therapy Considerations Guiding Initiation of Treatment in RET-Positive NSCLC

EP. 8: Considerations for First-Line Targeted Therapies in Metastatic RET-Positive NSCLC

EP. 9: Role of Immunotherapy and Chemotherapy in RET-Positive NSCLC

EP. 10: Managing RET Inhibitor Treatment-Related Adverse Events

EP. 11: Monitoring Patients With RET-Positive NSCLC

EP. 12: Unmet Needs and Future Perspectives of RET-Positive NSCLC

Dr Wakelee to Dr Sands: For clinicians who may not have access to “in-house” molecular testing at their institutional or community site and have to outsource these tests, are there any potential strategies to employ to ensure an appropriate turnaround time?
Dr Sands to Dr Wakelee: At your institution, how long does it typically take to receive the results for biomarker testing?